Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Denmark
In shortLeo Pharma A/s is profitable, generates cash and carries moderate debt, with revenue growing (+8.4% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 16.9% | 73/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 18.4% | 94/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 62.5% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 12.3% | 82/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.42× | 52/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.78× | 12/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 4.00× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 3.31× | 17/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.73 | 42/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 7.4% | 50/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.40× | 13/100 |
| Years with positive free cash flow (last 5) | 2 of 4 | 37/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 4 | 25/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 3 | 100/100 |
| Revenue growth volatility | 1.1% | 100/100 |
| Operating margin volatility | 19.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 8.3% | 63/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
DKK millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 10,641 | 11,392 | 12,453 | 13,499 |
| Cost of revenue | 4,358 | 4,281 | 4,935 | 5,259 |
| Gross profit | 6,283 | 7,111 | 7,518 | 8,240 |
| Research & development | 2,485 | 1,874 | 2,270 | 1,396 |
| Operating income | (3,311) | (1,699) | (1,143) | 2,279 |
| Interest expense | 785 | 1,140 | 946 | 688 |
| Pre-tax income | (4,093) | (2,792) | (1,957) | 1,713 |
| Income tax | 17 | 815 | (181) | (776) |
| Net income | (4,110) | (3,607) | (1,776) | 2,489 |
2.73 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Dec 31, 2025